Tazemetostat is an EZH2 inhibitor with an encouraging safety profile and response in both EZH2 wild-type and mutant relapsed/refractory (R/R) DLBCL, with responses up to 60% in R/R DLBCL (Radford et al., 2016; Italiano et al., 2018; Vincent Ribrag et al., 2018; Sarkozy et al., 2020). This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.